Braveheart Bio

Braveheart Bio (Ticker: BRVE US) develops therapies for hypertrophic cardiomyopathy and other serious cardiovascular diseases. Its candidate BHB-1893 is being evaluated for obstructive and non-obstructive hypertrophic cardiomyopathy. Braveheart Bio obtained exclusive licensing rights to BHB-1893 from Jiangsu Hengrui Pharmaceuticals, which discovered and initially developed the candidate. At the time of the profile, the company planned to begin a global Phase 3 trial for obstructive hypertrophic cardiomyopathy in the second half of 2026 and a Phase 3 trial for non-obstructive disease in the first half of 2027. The company had not generated product revenue at the time of the profile.

The scheduled listing date on Nasdaq was August 6, 2026. The proposed offering comprises 18,800,000 shares at an indicative price range of $15.00–17.00 per share. At the indicative range midpoint, the base offering would represent $300.80 million in gross proceeds, excluding any unexercised over-allotment.

Goldman Sachs, Jefferies, TD Cowen, Stifel and Cantor are managing the offering.